Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Axatilimab + CAR-T in High-Risk Lymphoma
NCT07638982Phase 1Not yet recruiting
- Sponsor
- Northside Hospital
- Start
- Dec 2026
- Primary completion
- Dec 2028
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of axatilimab in diffuse large B-cell lymphoma (DLBCL), high grade B-cell lymphoma (HGBCL), primary mediastinal large B-cell lymphoma (PMBCL) and 1 more, sponsored by Northside Hospital. Primary endpoints: Recommended Phase 2 Dose at 1 year and Progression-Free Survival at 1 year. Planned start Dec 2026; status: not yet recruiting.
02
Drugs
axatilimab
03
Conditions
diffuse large B-cell lymphoma (DLBCL)high grade B-cell lymphoma (HGBCL)primary mediastinal large B-cell lymphoma (PMBCL)follicular lymphoma (FL)
Beyond the preview
Go deeper on NCT07638982.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07638982.